Published in Clin Interv Aging on January 23, 2017
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation (2012) 30.79
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50
Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA (2001) 16.98
Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med (2007) 10.87
A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest (2010) 10.29
Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation (2015) 10.14
Apixaban in patients with atrial fibrillation. N Engl J Med (2011) 9.97
2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol (2014) 9.96
Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern Med (2015) 8.38
Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med (1987) 8.09
Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2013) 7.70
Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation (2011) 6.48
A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol (2011) 5.06
The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med (2009) 4.71
Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med (2012) 4.69
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med (2010) 4.01
Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke (2009) 3.89
Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation (2014) 3.53
Translating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation. Stroke (2006) 3.49
Newly identified events in the RE-LY trial. N Engl J Med (2010) 3.35
Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J (2006) 3.05
Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ (2015) 2.83
Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries, 1993-2007. Circ Cardiovasc Qual Outcomes (2012) 2.61
Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease. Circulation (2012) 2.56
Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. Ann Intern Med (2011) 2.45
Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J (2014) 2.32
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J (2011) 2.31
Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol (2013) 2.29
A systematic review of barriers to medication adherence in the elderly: looking beyond cost and regimen complexity. Am J Geriatr Pharmacother (2011) 2.26
Contemporary trends of hospitalization for atrial fibrillation in the United States, 2000 through 2010: implications for healthcare planning. Circulation (2014) 2.19
Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. J Am Coll Cardiol (2014) 2.18
Attitudes of physicians regarding anticoagulation for atrial fibrillation: a systematic review. Age Ageing (2011) 1.94
New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials. J Am Geriatr Soc (2014) 1.37
Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database Syst Rev (2007) 1.33
Mortality after ground-level fall in the elderly patient taking oral anticoagulation for atrial fibrillation/flutter: a long-term analysis of risk versus benefit. J Trauma Acute Care Surg (2014) 1.00
The elderly patient with acute renal failure. J Am Soc Nephrol (1995) 0.96
The aging kidney: increased susceptibility to nephrotoxicity. Int J Mol Sci (2014) 0.92
Additional events in the RE-LY trial. N Engl J Med (2014) 0.89
Is female sex a risk factor for stroke and thromboembolism in patients with atrial fibrillation? A systematic review and meta-analysis. QJM (2014) 0.87
An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics. J Clin Pharmacol (2015) 0.85
Barriers to anticoagulation in patients with atrial fibrillation: changing physician-related factors. Stroke (2007) 0.85
Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial. Age Ageing (2015) 0.84
The caregiver role in thromboprophylaxis management in atrial fibrillation: a literature review. Eur J Cardiovasc Nurs (2014) 0.83
Care transitions in anticoagulation management for patients with atrial fibrillation: an emphasis on safety. Ochsner J (2013) 0.82
Effect of preinjury warfarin use on outcomes after head trauma in Medicare beneficiaries. Am J Surg (2014) 0.80
Warfarin and Aspirin Use for Stroke Prevention Among Patients With Atrial Fibrillation: The US National Health and Wellness Survey. Am J Ther (2015) 0.79